








## DISTRIBUZIONE MONDIALE DELL'INCIDENZA DEL CANCRO

Figura 3









# Secondary Causes of Constipation

## Mechanical Obstruction

Anal stenosis

Colorectal cancer

Extrinsic compression

Rectocele or sigmoidocele

Stricture

## Medications

Antacids

**Anticholinergic agents** (antiparkinsonian, antipsychotics, antispasmodics, tricyclic antidepressants)

**Anticonvulsants** (carbamazepine, phenobarbital)

Antineoplastic agents (vinca derivatives)

Calcium channel blockers (verapamil)

Diuretics (furosemide)

5-HT<sub>3</sub> antagonists (e.g., alosetron)

**Iron supplements**

Nonsteroidal anti-inflammatory drugs

Mu-opioid agonists (loperamide, morphine)

## Metabolic and Endocrinologic Disorders

**Diabetes mellitus**

Heavy metal poisoning (e.g., arsenic, lead, mercury)

Hypercalcemia

Hyperthyroidism

Hypokalemia

**Hypothyroidism**

Panhypopituitarism

Pheochromocytoma

Porphyria

**Pregnancy**

## Neurologic and Myopathic Disorders

Amyloidosis

Autonomic neuropathy

Chagas' disease

Dermatomyositis

Intestinal pseudo-obstruction

**Multiple sclerosis**

Parkinsonism


Progressive systemic sclerosis


Shy-Drager syndrome

Spinal cord injury


Stroke

# INCIDENZA DEL CCR NEL MONDO





# MORTALITÀ DEL CCR NEL MONDO



## ■ IL CCR NEL MONDO

**Incidenza: 3º posto**

**~1'000'000 nuovi casi/anno**

**Mortalità: 2º posto**

**~500'000 morti/anno**

## ■ IL CCR IN EUROPA

**Incidenza<sup>1</sup> : 2<sup>o</sup> posto**

**~ 400'000 nuovi casi/anno**

**Mortalità<sup>1</sup> : 2<sup>o</sup> posto**

**~ 200'000 morti/anno**

**Sopravvivenza<sup>2</sup> : 53,5% (a 5 anni)**

1 - ESMO (European Society for Medical Oncology): Cancer epidemiology, 2007.

2 - The EUROCARE-4 study. The Lancet Oncology, 2007.

## ■ IL CCR IN ITALIA

**Incidenza: 2<sup>o</sup> posto (11,9%)<sup>1</sup>**

**~ 48'000(F 30%) nuovi casi/anno<sup>2</sup>**

**Mortalità: 2<sup>o</sup> posto (11,3%)<sup>1</sup>**

**~ 15'000(F 40%) morti/anno<sup>2</sup>**

**Sopravvivenza: 57,5% (a 5 anni)<sup>3</sup>**

1 - AIRTUM (Associazione Italiana Registri Tumori) : I nuovi dati di incidenza e mortalità (2003-2005). 2009

2 - Stime del CNESPS (Centro Nazionale Epidemiologia Sorveglianza Promozione Salute). 2009

3 - The EUROCARE-4 study. The Lancet Oncology. 2007

## ■ IL CCR IN EMILIA-ROMAGNA

**Incidenza:** ~ 4'000 nuovi casi/anno (13,9%)


**Mortalità:** ~ 1'500 morti/anno (11%)

**Sopravvivenza:** ~ 60% (a 5 anni)


# ■ IL CCR A FERRARA

## Incidenza e mortalità (1999-2002)

♂ Maschi



♀ Femmine




(Fonte AIRTUM)

# Numero di casi di cancro colorettale per AUSL per il periodo 2003-2009

Popolazione residente

in Regione Emilia-Romagna  
al 01/01/2010:  
4.395.606

Centro	Totale casi	% di casi per centro	Numero medio annuo di casi
Piacenza	1,635	6.4	273
Parma	2,818	11.0	403
Reggio E.	2,392	9.3	399
Modena	3,978	15.5	663
Bologna	3,499	13.6	875
Imola	904	3.5	129
Ferrara	2,451	9.6	490
Ravenna	3,110	12.1	444
Forlì	1,374	5.4	196
Cesena	1,392	5.4	199
Rimini	2,096	8.2	299
Totale RER	25,649	100.0	4370



# Increasing incidence of colorectal cancer in Asia: implications for screening

Joseph J Y Sung, James YW Lau, KL Goh, WK Leung, for the Asia Pacific Working Group on Colorectal Cancer\*






Figure 3: Mortality rates of colorectal cancer in five Asian countries in (A) men and (B) women, 1955–99\*

# Fattori di rischio

- Stile di vita



- Fattori ereditari



- Età: l'incidenza aumenta 10 volte dalla IV alla VI decade

- Malattie dell'intestino



# Fattori di rischio individuali

- Età  $\geq$  50 aa
  - 90% CCR si sviluppa da 50 aa. In poi
  - Da 50 a 80 aa il rischio di CCR =  $\times 2.5$
- Polipi adenomatosi non FAP
  - +frequente dopo 50 aa
  - La trasformazione da adenoma a carcinoma varia da 3 a 37% in base alla dimensione e al grado di atipia
- Storia familiare di CCR
  - La presenza nei genitori: comporta un rischio  $\times 2$ ,  $\times 3$
- Storia familiare di polipi adenomatosi
- Poliposi familiare nel colon (adenomatose e amartomatose)
- Hereditary non-polyposis colorectal cancer (HNPCC)
- Malattie infiammatorie intestinali (Colite ulcerosa e M. di Crohn)
  - Stretta correlazione con la durata della malattia e l'andamento clinico (+recidive = + rischio)

# Fattori di rischio ambientali

## ■ Fattori favorenti l'insorgenza



- Carcinogeni e mutageni ambientali
- Amine etrocicliche
- Prodotti del metabolismo batterico
- Consumo di alcol
- Fumo
- Sovrappeso, vita sedentaria

## Fattori protettivi



**Dieta ricca di fibre vegetali  
Cruciferi (cavoli, rape, etc..)**

**Vitamine antiossidanti (vitamina C ed E)**

**Assunzione di folati**

**Consumo di aspirina e inibitori della COX-2**

**Table 123-1** Factors That May Influence Carcinogenesis in the Colon and Rectum

**Probably Causative**

High-fat and low-fiber diet (adjusted for energy intake)\*

Red meat consumption

**Possibly Causative**

Beer and ale consumption (especially for rectal cancer)

Cigarette smoking

Diabetes mellitus

Environmental carcinogens and mutagens

Heterocyclic amines (from charbroiled and fried meat and fish)

Low dietary selenium

**Probably Protective**

Aspirin, NSAIDs, and cyclooxygenase-2 inhibitors

Calcium

Hormone replacement therapy (estrogen)

Low body mass

Physical activity

**Possibly Protective<sup>†</sup>**

Carotene-rich foods

High-fiber diet

Vitamins C and E


Vitamin D

Yellow-green cruciferous vegetables

# Nonlinear Reduction in Risk for Colorectal Cancer by Fruit and Vegetable Intake Based on Meta-analysis of Prospective Studies

DAGFINN AUNE,\* ROSA LAU,\* DORIS S. M. CHAN,\* RUI VIEIRA,\* DARREN C. GREENWOOD,‡ ELLEN KAMPMAN,§ and TERESA NORAT\*

\*Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK; ‡Biostatistics Unit, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, UK; §Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands



To our knowledge this is also the first meta-analysis to explore the potential nonlinear association of fruit and vegetable intake with colorectal cancer risk. Although some caution is needed in interpreting the exact quantities and size of the risk estimates because of the measurement errors associated with use of the dietary assessment methods, *our results indicate that there is a low threshold level of between 100 and 200 g/d that can reduce risk about 10%. Above that level there seems to be no additional benefit of increasing vegetable intake in terms of colorectal cancer risk, and for fruit a slight further reduction with higher intakes is observed (an approximate 15% reduction for an intake of 600 g/d).*

## **Nonlinear Reduction in Risk for Colorectal Cancer by Fruit and Vegetable Intake Based on Meta-analysis of Prospective Studies**

DAGFINN AUNE,\* ROSA LAU,\* DORIS S. M. CHAN,\* RUI VIEIRA,\* DARREN C. GREENWOOD,† ELLEN KAMPMAN,§ and TERESA NORAT\*

\**Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK;* †*Biostatistics Unit, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, UK;* §*Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands*

**Fruit and vegetables are also good sources of folate, which has been associated with decreased risk of colorectal cancer in a number of studies, but not all studies.**

**Folate plays an important role in DNA methylation and is necessary for synthesis of thymine.**

**Folate deficiency can lead to misincorporation of uracil instead of thymine into DNA and increase the number of chromosomal breaks.**

**In addition, fruit and vegetables are good sources of various antioxidants, vitamins, minerals, and other bioactive compounds, which might prevent cancer**

# **PREVENZIONE PRIMARIA**

- Norme dietetiche
- Controllo di alcune abitudini voluttuarie
- Mantenimento del peso ideale
- Utilizzo di farmaci

# ■ NORME DIETETICHE



**CARNI ROSSE**




**PESCE e POLLAME**



**VERDURA, FRUTTA  
CEREALI, LEGUMI:**

⇒ fibre, antiossidanti, folati



# Effetto della Fibra sul



## transito intestinale



### LA FIBRA SOLUBILE (pectine, gomme, mucillaggini, Galattomannani)

fermentabile, ha proprietà chelanti, ovvero tende a formare un composto gelatinoso all'interno del lume intestinale; questo gel che si viene a formare aumenta la viscosità del contenuto con conseguente rallentamento dello svuotamento intestinale. Tuttavia le sue proprietà chelanti fanno sì che essa interferisca con l'assorbimento di alcuni macronutrienti (glucidi e lipidi) riducendo i livelli di colesterolo nel sangue e diminuendo il rischio di malattie cardiovascolari.

### LA FIBRA INSOLUBILE, cellulosa, emicellulosa, lignina

non fermentabile, assorbe rilevanti quantità acqua aumentando il volume delle feci, che si fanno abbondanti, poltacee e più morbide. Questo permette di stimolare la velocità di transito nel lume intestinale, di conseguenza, diminuire l'assorbimento dei nutrienti. Questo spiega perché la *fibra solubile* abbia, al contrario di quella insolubile, più azione *costipante* che lassativa (a meno che non venga assunta insieme a grosse quantità di liquidi).

## ■ CONTROLLO DI ALCUNE ABITUDINI VOLUTTUARIE

 **FUMO**



 **ALCOOL**

## ■ MANTENIMENTO DEL PESO IDEALE

 **ATTIVITÀ FISICA**

 **OBESITÀ**

Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study



# Metabolic Factors and the Risk of Colorectal Cancer in 580,000 Men and Women in the Metabolic Syndrome and Cancer Project (Me-Can), Stocks, Cancer 2011

## Original Article

**Table 2.** The Relative Risk of Incident Colorectal Cancer in Men and Women by Quintiles of Metabolic Factors<sup>a</sup>



Exposure	Q	Men			Women		
		Mean±SD	No. of Cases	RR (95% CI)	Mean±SD	No. of Cases	RR (95% CI)
BMI, kg/m <sup>2</sup>	1	21.5±1.3	399	1.00 (Referent)	20.0±1.2	233	1.00 (Referent)
	2	23.8±0.8	484	1.08 (0.93-1.26)	22.3±0.8	297	1.04 (0.87-1.27)
	3	25.4±0.8	588	1.22 (1.06-1.41)	24.1±0.8	372	1.10 (0.92-1.33)
	4	27.1±0.9	642	1.27 (1.10-1.46)	26.4±1.0	439	1.12 (0.93-1.35)
	5	30.8±2.8	721	1.51 (1.32-1.73)	31.7±3.6	520	1.29 (1.09-1.55)

In line with findings from previous studies, in our study, high BMI was related more strongly to colon cancer than to rectal cancer, and the association was stronger in men than in women.<sup>24-26</sup> However, the use of BMI as a measure of obesity is hampered by the finding that **BMI is not a specific measure of abdominal fat mass**, which is linked to metabolic aberrations, such as insulin resistance. High abdominal obesity, assessed as the **waist circumference or as the waist-to-hip ratio**, have been associated with an increased risk of colorectal cancer risk in men; whereas, in women, waist measures, but not BMI, have been associated positively with risk.

La circonferenza vita è un indicatore del tessuto adiposo viscerale

**Uomini** >102 cm = Rischio aumentato

**Donne** >88 cm = Rischio aumentato



## Risk factors for colonic and rectal cancer mortality: evidence from 40 years' follow-up in the Whitehall I study

David S Morrison,<sup>1</sup> George David Batty,<sup>2</sup> Mika Kivimaki,<sup>3</sup> George Davey Smith,<sup>4</sup> Michael Marmot,<sup>3</sup> Martin Shipley<sup>3</sup>

.....A significant effect of current smoking on rectal cancer mortality was only apparent after events in the first 10 years of follow-up were excluded.

No convincing evidence was found that body mass index, diabetes mellitus, blood pressure or physical activity were associated with colorectal cancer mortality.

*Conclusion Smoking significantly increases mortality from colorectal cancer and its decreasing prevalence in the UK may partly explain falling mortality from the disease.*

# PREVENZIONE SECONDARIA

## ↓ SCREENING

### Test di screening:

- ✓ Test ricerca sangue occulto fecale (SOF)
- ✓ Rettosigmoidoscopia
- ✓ Combinazione SOF + rettosigmoidoscopia
- ✓ Pancolonscopia

### Test complementare:

- ✓ Colografia-TC

# SOF immunologico

✓ **sensibile:**

sensibilità 78%

✓ **specifico:**

specificità 93%, > specificità per sanguinamenti colici

✓ **riproducibile:**

metodo quantitativo ( $\Rightarrow$  cut off a 100ng/ml = concentrazione di emoglobina nel campione), lettura automatizzata, laboratorio unico per tutta la Provincia

✓ **esente da complicazioni:**

non invasivo, innocuo

✓ **accettabile dalla popolazione target:**

facile esecuzione, campione singolo, non richiede restrizioni dietetiche

✓ **conveniente:**

miglior rapporto costo-beneficio

# PANCOLONSCOPIA

- ✓ Gold standard delle metodiche di screening
- ✓ Sensibilità ~ 90%
- ✓ Specificità ~ 100%
- ✓ possibilità di diagnosi e di trattamento terapeutico
- ✓ **POLIPECTOMIA**
  - riduce l'incidenza di CCR del 75%
  - riduce la mortalità del 69%
- ✓ **indicatori di qualità per la pancolonoscopia**
  - tasso di intubazione ciecale (> 90% diagnostica e >95% screening)
  - tempo di retrazione dell'endoscopio (> 6 minuti)
  - tasso di identificazione degli adenomi ( ♂ > 25%, ♀ >15%)

# Biennio 2005-2007 Ferrara

## Persone invitate ad eseguire FOBT-test



49749

26156

Donne

23593

Uomini

Il FOBT-test è stato eseguito da 21432 persone (43.4%)

1281 FOBT positivi  
(5.9%)

20149 FOBT negativi  
(94.1%)

1155 (91%) hanno accettato la colonscopia




# Colorectal cancer molecular biology moves into clinical practice

Colin C Pritchard,<sup>1</sup> William M Grady<sup>2,3</sup>

## MOLECULAR MECHANISMS OF COLORECTAL CARCINOGENESIS

### The adenoma/carcinoma progression sequence


Colorectal cancer arises as the result of the accumulation of acquired genetic and epigenetic changes that transform normal glandular epithelial cells into invasive adenocarcinomas. Steps that





## Suddivisione Percentuale delle forme di CCR

Sporadico




Familiare/Ereditario



La maggior parte dei CCR insorge da una lesione sporadica che inizia con una iperplasia, e segue..... Adenoma, Adenoma cancerizzato, Adenocarcinoma.




Delezione o mutazione “non senso”  
del gene APC (Adenomatous Polyposis)



# La sequenza Adenoma-Carcinoma

(Bert Vogelstein)



K-ras = Mutazione di Protoncogene, nel  
10% degli Adenomi;  
60% dei CCR

Smad4 = è alterato nel 30% dei CCR

p53 = quando mutato si perde la regolazione del  
ciclo cellulare ed è mutato nel 70% dei CCR